Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 354 | 0.91 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 9034
Sealed predictions
- CEBPD in dopamine neurons, braak-0.08 (p 0.842) → -0.34 (p 0.373)receipt 9041
Swarm cases
receipt 9041: CEBPD in dopamine neurons, braak
- power
- full sample -0.18 (p 0.465, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.17 (p 0.493, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.493, n 18). could be the mix.
- skeptic
- leave-one-out range -0.26 to -0.07, sign flips 0; without severely affected donors -0.18 (p 0.465, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CEBPD in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts